AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21861690 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic‐Own‐Signal‐Treatment (EMOST)
Number of subjects: 15
Study 21861690 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 15
Study 19761114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-electroacupuncture (Ear-EA)
Number of subjects: 80
Study 19761114 — intervention group
Group type: COMPARATOR
Intervention: Body-electroacupuncture (body-EA)
Number of subjects: 80
Study 17208119 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month program (weight loss, low-sodium diet, high in fruit, vegetables, and fish, increased physical activity)
Number of subjects: 241
Study 17208119 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month program
Number of subjects: 241
Study 16573544 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant doxorubicin (10 mg/m² weekly, starting from acceptance onto the waiting list for LT, with one intraoperative dose of 15 mg/m² and postoperative doses depending on clinical course, up to a cumulative dose of 400 mg/m²)
Number of subjects: 46
Study 16573544 — intervention group
Group type: COMPARATOR
Intervention: LT alone (control group)
Number of subjects: 46
Study 14520776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth whitening gel containing 25% carbamide peroxide
Number of subjects: 59
Study 14520776 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth whitening gel containing 8.7% hydrogen peroxide
Number of subjects: 59
Study 10582982 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Stroke Education Program (SEP)
Number of subjects: 204
Study 10582982 — intervention group
Group type: COMPARATOR
Intervention: Conventional stroke unit care
Number of subjects: 204
Study 8753940 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing interstimulus interval (ISI) during noxious sural nerve stimulation
Number of subjects: 0
Study 8753940 — intervention group
Group type: COMPARATOR
Intervention: Noxious sural nerve stimulation
Number of subjects: 0
Study 1812432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuban vaccine against group B Neisseria meningitidis
Number of subjects: 106000
Study 6341912 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRF 159 plus radiotherapy
Number of subjects: 70
Study 6341912 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus radiotherapy
Number of subjects: 70
Study 29532416 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and 800 mg inulin) for 12 weeks
Number of subjects: 60
Study 29532416 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 60
Study 28859679 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at lunch
Number of subjects: 478
Study 28859679 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular face-to-face interaction
Number of subjects: 478
Study 28859679 — intervention group
Group type: COMPARATOR
Intervention: Private offices
Number of subjects: 478
Study 25074734 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month aerobic walking group
Number of subjects: 179
Study 25074734 — intervention group
Group type: COMPARATOR
Intervention: Strengthening and flexibility group
Number of subjects: 179
Study 22373777 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft plus modified glass ionomer restoration (CTG+R)
Number of subjects: 34
Study 22373777 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft only (CTG)
Number of subjects: 34
Study 21721073 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 42
Study 21721073 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 42
Study 19820754 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril 20 mg/day)
Number of subjects: 12
Study 19820754 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor + Angiotensin receptor blocker (lisinopril 10 mg/day + candesartan 16 mg/day)
Number of subjects: 12
Study 19820754 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonist (eplerenone 25 mg/day)
Number of subjects: 12
Study 16384629 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with medial frontal lobe damage (ACC involvement)
Number of subjects: 2
Study 16384629 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (age and education matched)
Number of subjects: 2
Study 16335646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose quinine (10 mg/kg 2 times/day)
Number of subjects: 42
Study 16335646 — intervention group
Group type: COMPARATOR
Intervention: Standard quinine (10 mg/kg 3 times/day)
Number of subjects: 42
Study 16335646 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 11077029 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 1200 mg/day in two divided doses
Number of subjects: 46
Study 11077029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsule)
Number of subjects: 46
Study 9217894 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with saline
Number of subjects: 15
Study 9217894 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with indomethacin (0.65 microgram/kg/min)
Number of subjects: 15
Study 9217894 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with L-NMMA (30 micrograms/kg/min)
Number of subjects: 15
Study 9217894 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with propranolol (0.2 microgram/kg/min)
Number of subjects: 15
Study 9217894 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (0.65 microgram/kg/min) alone
Number of subjects: 15
Study 9217894 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (30 micrograms/kg/min) alone
Number of subjects: 15
Study 8453955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 50
Study 8453955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2422461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 34
Study 2422461 — intervention group
Group type: COMPARATOR
Intervention: Intravenous digoxin
Number of subjects: 34
Study 2422461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (definite infarction subgroup)
Number of subjects: 34
Study 2422461 — intervention group
Group type: COMPARATOR
Intervention: Intravenous digoxin (definite infarction subgroup)
Number of subjects: 34
Study 2422461 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither drug
Number of subjects: 34
Study 27960578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless scleral tunnel trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 34
Study 27960578 — intervention group
Group type: COMPARATOR
Intervention: Conventional trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 34
Study 27770820 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with 12 once-weekly sessions and voucher rewards for cannabis-free urinalysis
Number of subjects: 544
Study 27770820 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 544
Study 27770820 — intervention group
Group type: COMPARATOR
Intervention: Optimised Treatment as Usual (OTAU) psychoeducational package
Number of subjects: 544
Study 25653151 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii CNCM I-745
Number of subjects: 363
Study 23905488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50 mg daily for 12 weeks)
Number of subjects: 45
Study 23905488 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (600 mg parenterally for 7 days, followed by 600 mg orally for 12 weeks)
Number of subjects: 45
Study 23905488 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Transdermal testosterone and Alpha-lipoic acid)
Number of subjects: 45
Study 21090960 — intervention group
Group type: EXPERIMENTAL
Intervention: SADV (coordinated substance abuse and domestic violence treatment program)
Number of subjects: 69
Study 21090960 — intervention group
Group type: COMPARATOR
Intervention: TSF (Twelve Step Facilitation)
Number of subjects: 69
Study 18355589 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric osteotomy
Number of subjects: 50
Study 18355589 — intervention group
Group type: COMPARATOR
Intervention: Conventional saw and chisel osteotomies
Number of subjects: 50
Study 17029131 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine
Number of subjects: 96
Study 17029131 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine
Number of subjects: 96
Study 17029131 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (single dose)
Number of subjects: 96
Study 12683473 — intervention group
Group type: EXPERIMENTAL
Intervention: auto-nCPAP
Number of subjects: 35
Study 12683473 — intervention group
Group type: COMPARATOR
Intervention: conventional nCPAP
Number of subjects: 35
Study 12755665 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 56
Study 12755665 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 56
Study 12755665 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 56
Study 12755665 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 56
Study 12755665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 56
Study 10573548 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral vitamin A
Number of subjects: 56
Study 10573548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8561324 — intervention group
Group type: EXPERIMENTAL
Intervention: IV clonidine treatment
Number of subjects: 24
Study 8561324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 24
Study 1919058 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR (solar-simulated radiation)
Number of subjects: 18
Study 1919058 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR/S (solar-simulated radiation plus UVB sunscreen)
Number of subjects: 18
Study 1919058 — intervention group
Group type: EXPERIMENTAL
Intervention: SSR/S/5‐MOP (solar-simulated radiation plus UVB sunscreen with 5-methoxypsoralen at 30 ppm)
Number of subjects: 18
Study 1919058 — intervention group
Group type: COMPARATOR
Intervention: Control (no SSR or topical treatment)
Number of subjects: 18
Study 6882818 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG plus thermal biofeedback
Number of subjects: 45
Study 6882818 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal biofeedback
Number of subjects: 45
Study 6882818 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 45
Study 30712533 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (15Hz) targeting the left PMC/DLPFC for 15 days
Number of subjects: 0
Study 30712533 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 0
Study 30203386 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 40 mg alone
Number of subjects: 18
Study 30203386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg for 5 days
Number of subjects: 18
Study 30203386 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil 40 mg with oseltamivir 75 mg for 5 days
Number of subjects: 18
Study 29071880 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimusake Tablets at 1.5 g per night for 8 weeks (group A)
Number of subjects: 180
Study 29071880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine hydrochloride at 30 mg 1-3 hours before sexual activity for 8 weeks (group B)
Number of subjects: 180
Study 29071880 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimusake Tablets plus dapoxetine hydrochloride for 8 weeks (group C)
Number of subjects: 180
Study 24258250 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching intervention by trained coaches
Number of subjects: 109
Study 23244155 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational program (eight 90 minute weekly sessions)
Number of subjects: 76
Study 23244155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychoeducational intervention)
Number of subjects: 76
Study 20648044 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of mono- and polyunsaturated fat
Number of subjects: 2551
Study 20648044 — intervention group
Group type: COMPARATOR
Intervention: Total fat intake or different types of fat
Number of subjects: 2551
Study 17939477 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina-alumina bearing surfaces
Number of subjects: 140
Study 17939477 — intervention group
Group type: COMPARATOR
Intervention: Metal-polyethylene bearing surfaces
Number of subjects: 140
Study 15530585 — intervention group
Group type: EXPERIMENTAL
Intervention: Short bouts (SB; 3 x 10 min/day)
Number of subjects: 40
Study 15530585 — intervention group
Group type: EXPERIMENTAL
Intervention: Long bouts (LB; 30 min/day)
Number of subjects: 40
Study 11898013 — intervention group
Group type: EXPERIMENTAL
Intervention: L5-S1 spinal manipulation
Number of subjects: 24
Study 11898013 — intervention group
Group type: COMPARATOR
Intervention: Side-posture positioning (control)
Number of subjects: 24
Study 9427568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln-PN
Number of subjects: 0
Study 9427568 — intervention group
Group type: COMPARATOR
Intervention: Standard Gln-free PN
Number of subjects: 0
Study 10150702 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical malpractice cases
Number of subjects: 0
Study 10150702 — intervention group
Group type: COMPARATOR
Intervention: Negligent driving cases
Number of subjects: 0
Study 2752040 — intervention group
Group type: EXPERIMENTAL
Intervention: TXB2 infusion at 0.1 ng.kg‐1.min‐1
Number of subjects: 4
Study 2752040 — intervention group
Group type: EXPERIMENTAL
Intervention: TXB2 infusion at 1.0 ng.kg‐1.min‐1
Number of subjects: 4
Study 2752040 — intervention group
Group type: EXPERIMENTAL
Intervention: TXB2 infusion at 5.0 ng.kg‐1.min‐1
Number of subjects: 4
Study 2752040 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion (control)
Number of subjects: 4
Study 2752040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (325 mg/d)
Number of subjects: 4
Study 2752040 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous TXB2 entry rate calculation
Number of subjects: 4
Study 616222 — intervention group
Group type: EXPERIMENTAL
Intervention: lynestrenol 0.5 mg
Number of subjects: 27
Study 616222 — intervention group
Group type: EXPERIMENTAL
Intervention: lynestrenol 0.5 mg + ethinyl estradiol 0.05 mg
Number of subjects: 27
Study 616222 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐norgestrel 0.25 mg + ethinyl estradiol 0.05 mg
Number of subjects: 27
Study 29605029 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with fluorouracil, epirubicin, and cyclophosphamide
Number of subjects: 122
Study 28545625 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking program (intervention group)
Number of subjects: 54
Study 28545625 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (control group)
Number of subjects: 54
Study 28545625 — intervention group
Group type: COMPARATOR
Intervention: Healthy sex- and age-matched participants (control for respiratory endurance variables)
Number of subjects: 54
Study 26173528 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed reflection on diagnoses
Number of subjects: 47
Study 26173528 — intervention group
Group type: COMPARATOR
Intervention: Pass 1 diagnoses
Number of subjects: 47
Study 26173528 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised diagnoses
Number of subjects: 47
Study 23030716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/day) for 6 weeks before surgery
Number of subjects: 142
Study 23030716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dutasteride)
Number of subjects: 142
Study 21942303 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 0
Study 21942303 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 0
Study 21942303 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 18206394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical depression fracture present
Number of subjects: 121
Study 18206394 — intervention group
Group type: COMPARATOR
Intervention: No cortical depression fracture
Number of subjects: 121
Study 18206394 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at injury
Number of subjects: 121
Study 18206394 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscal tears
Number of subjects: 121
Study 17190950 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiepileptic treatment
Number of subjects: 419
Study 17190950 — intervention group
Group type: COMPARATOR
Intervention: Treatment only in the event of seizure recurrence
Number of subjects: 419
Study 12701462 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic group training three times a week for three months (n = 50)
Number of subjects: 93
Study 12701462 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 51)
Number of subjects: 93
Study 12701462 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic group training (n = 50)
Number of subjects: 93
Study 11502779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoids (methylprednisolone; 15 mg/kg for four cycles and then 7.5 mg/kg for four cycles; each cycle consisted of two infusions on alternate days at 2‐wk intervals)
Number of subjects: 82
Study 11502779 — intervention group
Group type: COMPARATOR
Intervention: Oral glucocorticoids (prednisone; starting dose, 100 mg/d; withdrawal after 5 months)
Number of subjects: 82
Study 9214325 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted laparoscopic resection (ALR)
Number of subjects: 41
Study 9214325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection-facilitated laparoscopic resection (DLR)
Number of subjects: 41
Study 9214325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy (conversion from laparoscopic approach)
Number of subjects: 41
Study 9214325 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 41
Study 9214325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean hospital stay
Number of subjects: 41
Study 8500314 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment via mass media
Number of subjects: 577
Study 8500314 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment at worksites
Number of subjects: 577
Study 8500314 — intervention group
Group type: COMPARATOR
Intervention: Recruitment at community events
Number of subjects: 577
Study 8500314 — intervention group
Group type: COMPARATOR
Intervention: Direct mail recruitment
Number of subjects: 577
Study 3545246 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning transcutaneous electrical nerve stimulators (TENS)
Number of subjects: 100
Study 3545246 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (300-600 mg with 30-60 mg codeine) and functioning TENS
Number of subjects: 100
Study 3545246 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 100
Study 3545246 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine (300-600 mg with 30-60 mg codeine) and placebo TENS
Number of subjects: 100
Study 2571492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefetamine administered to opiate addicts with acute withdrawal syndrome
Number of subjects: 30
Study 2571492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefetamine tested in naloxone and pentazocine tests
Number of subjects: 30
Study 30470457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program (10 sessions of 45 minutes each, one per week) focusing on memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration, and programming.
Number of subjects: 201
Study 30470457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cognitive stimulation program).
Number of subjects: 201
Study 30789018 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo dry powder inhaler
Number of subjects: 537
Study 29956905 — intervention group
Group type: EXPERIMENTAL
Intervention: Guasha therapy
Number of subjects: 65
Study 29956905 — intervention group
Group type: COMPARATOR
Intervention: Sham scraping
Number of subjects: 65
Study 29956905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 26512691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk with added fructose containing sugars (50th percentile of fructose consumption)
Number of subjects: 0
Study 26512691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk sweetened with glucose
Number of subjects: 0
Study 26512691 — intervention group
Group type: COMPARATOR
Intervention: Unsweetened low-fat milk (control group)
Number of subjects: 0
Study 24124482 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (I)
Number of subjects: 80
Study 24124482 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with CRI of ketamine (IK)
Number of subjects: 80
Study 24124482 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with CRI of propofol (IP)
Number of subjects: 80
Study 24124482 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with CRI of fentanyl (IF)
Number of subjects: 80
Study 24124482 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups IK and IF
Number of subjects: 80
Study 24124482 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups IF and IK
Number of subjects: 80
Study 21088594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation model simulator training
Number of subjects: 60
Study 21088594 — intervention group
Group type: COMPARATOR
Intervention: Computer-based DVD training
Number of subjects: 60
Study 19475666 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 28
Study 19475666 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine + CIAT
Number of subjects: 28
Study 19475666 — intervention group
Group type: COMPARATOR
Intervention: CIAT
Number of subjects: 28
Study 19475666 — intervention group
Group type: COMPARATOR
Intervention: Switching to Memantine from Placebo
Number of subjects: 28